The Centers for Medicare and Medicaid Services on Monday finalized a 5.06% increase in payments to Medicare Advantage plans for 2026, a figure that exceeded Wall Street expectations and sent shares of the nation’s largest health insurers sharply higher. UnitedHealth Group, Humana, CVS Health, and Cigna all posted significant gains in a single session, reversing months of sector anxiety that had gripped investors since late 2024.
The rally was immediate and broad. UnitedHealth Group climbed more than 8%. Humana surged roughly 11%. CVS Health rose about 7%, and Cigna gained approximately 5%, according to Yahoo Finance. For an industry that had been battered by a combination of rising medical costs, regulatory uncertainty, and the fallout from the assassination of UnitedHealthcare CEO Brian Thompson in December 2024, the announcement felt like a pressure valve releasing.
But behind the headline number lies a more complex calculation — one that reveals how the federal government is trying to balance fiscal discipline with the political reality that more than 33 million Americans now depend on Medicare Advantage plans for their health coverage.
The 5.06% rate increase represents the final payment rate for calendar year 2026, and it’s notably higher than the initial 4.33% proposed earlier this year. CMS had published its advance notice in January, signaling a more modest bump. Insurers and their lobbyists pushed back hard, arguing that medical cost trends — particularly in outpatient care, pharmacy spending, and behavioral health — demanded a larger adjustment. The final number suggests CMS listened, at least partially.
To understand why this matters so much, consider the math. Medicare Advantage plans are paid a per-member, per-month capitated rate by the federal government. These rates are benchmarked against traditional fee-for-service Medicare costs, then adjusted for the health status of enrollees through a system known as risk adjustment. When CMS raises the base rate, insurers receive more money for each enrollee they cover. When it cuts or holds rates flat, margins compress — and benefits to seniors can shrink.
The industry had reason to worry. In 2024, CMS finalized a rate increase of approximately 3.7%, which insurers argued was insufficient given the surge in medical utilization following the pandemic. Seniors were returning to doctors’ offices and hospitals at rates that exceeded pre-COVID baselines. Supplemental benefits — things like dental coverage, vision care, hearing aids, and even grocery allowances — were being trimmed by plans struggling to maintain profitability.
Humana was hit hardest. The Louisville-based insurer, which derives a larger share of its revenue from Medicare Advantage than any other major publicly traded competitor, saw its stock price crater in 2024 after issuing multiple warnings about elevated medical costs. Its medical loss ratio — the percentage of premium revenue spent on actual medical care — climbed well above targets. The company’s CEO, Jim Rechtin, who took over from Bruce Broussard, has been working to stabilize operations and restore investor confidence.
Monday’s rate announcement helps. A lot.
The 5.06% increase translates to billions of additional dollars flowing into the Medicare Advantage system. For Humana alone, with its roughly 5.6 million Medicare Advantage members, even a single percentage point of additional rate increase can mean hundreds of millions in incremental revenue. For UnitedHealth Group, which covers more than 8 million Medicare Advantage enrollees through its UnitedHealthcare division, the impact is even larger in absolute terms.
And yet the stock rally also reflects something less tangible: relief. The managed care sector had been trading under a cloud of uncertainty that went beyond rate notices. Congressional scrutiny of Medicare Advantage billing practices — particularly allegations that insurers were inflating risk scores to extract higher payments from the government — had intensified throughout 2024 and into 2025. The Department of Justice has active investigations into several major insurers’ risk adjustment practices. UnitedHealth Group, in particular, has faced pointed questions about its Optum health services division and the degree to which vertical integration creates conflicts of interest.
The Thompson assassination in December 2024 added an entirely different dimension of risk. Public anger at health insurers, simmering for years over prior authorization denials and claims disputes, boiled over in the aftermath. Social media reaction was disturbingly sympathetic to the gunman. Insurers suddenly faced not just financial and regulatory headwinds, but reputational ones that threatened to reshape the political environment around healthcare.
Against that backdrop, a generous rate increase from CMS sends a signal. The Biden administration — and now the Trump administration, which took office in January 2025 — appears unwilling to starve the Medicare Advantage program of funding, regardless of the political noise. The program has become too popular with seniors and too embedded in the healthcare delivery system to dismantle through rate cuts.
This is a point that industry analysts have been making for months. Medicare Advantage enrollment has grown from roughly 11 million in 2010 to more than 33 million today. More than half of all Medicare-eligible Americans now choose a private Medicare Advantage plan over traditional fee-for-service Medicare. The program’s growth has been driven by supplemental benefits that traditional Medicare doesn’t offer, lower out-of-pocket costs for many enrollees, and aggressive marketing by insurers.
That growth creates its own political gravity. Any administration that tried to meaningfully cut Medicare Advantage rates would face a backlash from tens of millions of seniors — a voting bloc that no politician ignores lightly. So the rates go up.
The question is whether 5.06% is enough. Medical cost trend for 2025 and 2026 is running in the range of 6% to 8% by most industry estimates, driven by hospital price increases, GLP-1 drug utilization for diabetes and obesity, and a persistent labor shortage among nurses and other clinical staff that keeps wages elevated. If trend outpaces the rate increase, insurers will still face margin pressure — just less of it than they would have under the originally proposed 4.33%.
Wall Street analysts were quick to weigh in. Several upgraded their outlooks for managed care stocks following the announcement, noting that the final rate was approximately 70 to 75 basis points above the advance notice. That gap between proposed and final rates is wider than the historical average, suggesting CMS was responsive to industry feedback during the comment period.
But not everyone is celebrating. Consumer advocates and some health policy researchers argue that higher Medicare Advantage payments ultimately come from taxpayers and that the program already costs the government more per beneficiary than traditional Medicare. The Medicare Payment Advisory Commission, known as MedPAC, has repeatedly found that Medicare Advantage plans are paid, on average, 6% more than what it would cost to cover the same beneficiaries under traditional Medicare. Critics say that premium is unjustified and that insurers pocket much of the excess through risk score gaming rather than passing it along to seniors in the form of better benefits.
These criticisms aren’t new. They’ve persisted through multiple administrations of both parties. And they haven’t stopped the program from growing or rates from increasing. The political economy of Medicare Advantage is, at this point, self-reinforcing: more enrollees mean more political support, which means more funding, which means more benefits, which attracts more enrollees.
For UnitedHealth Group specifically, the rate increase arrives during a turbulent period. The company’s stock had been under significant pressure in early 2025, driven by a combination of the Thompson assassination aftermath, ongoing DOJ scrutiny, and concerns about medical cost trends in its commercial and Medicare businesses. The 8% single-day jump on the rate announcement recovers only a fraction of the ground lost over the preceding months.
The company remains the largest player in American health insurance by virtually every measure — revenue, enrollment, market capitalization. Its Optum division, which encompasses physician practices, pharmacy benefit management, data analytics, and care delivery, generates more revenue than the insurance business itself. That diversification is both a strength and a source of regulatory concern, as lawmakers increasingly question whether a single corporation should control so many links in the healthcare chain.
Humana’s situation is more straightforward and more precarious. The company is essentially a pure-play Medicare Advantage bet. When MA rates go up, Humana benefits disproportionately. When they stagnate or fall, Humana suffers disproportionately. Monday’s announcement is unambiguously positive for Humana’s 2026 outlook, but the company still needs to demonstrate that it can manage medical costs effectively after a bruising 2024.
CVS Health, which owns Aetna, has its own set of complications. The company’s Medicare Advantage business is meaningful but represents a smaller share of total revenue than it does for Humana or UnitedHealth. CVS is simultaneously trying to transform its retail pharmacy footprint, manage the integration of its health services businesses, and deal with competitive pressure in pharmacy benefit management from Mark Cuban’s Cost Plus Drugs and Amazon Pharmacy. The rate increase helps the Aetna division but doesn’t address CVS’s broader strategic challenges.
Cigna, now operating as The Cigna Group after spinning off its individual Medicare Advantage business to Health Care Service Corporation, has less direct exposure to the MA rate announcement than its peers. But the company still participates in Medicare through its Evernorth health services division and through group Medicare products. Its stock rose in sympathy with the sector.
So where does this leave the industry heading into 2026? In better shape than it was 48 hours ago, certainly. The 5.06% rate increase provides a financial cushion that should allow most major insurers to stabilize or even expand their Medicare Advantage benefit packages for the coming year. Seniors may see the return of some supplemental benefits that were trimmed in 2025. Broker commissions, which had been cut by some plans, may be restored.
But the underlying tensions haven’t gone away. Medical costs are still rising faster than many actuaries predicted. The GLP-1 drug class — Ozempic, Wegovy, Mounjaro, Zepbound — represents a potential fiscal earthquake for insurers if utilization continues to climb. These drugs cost $1,000 or more per month, and while they may reduce downstream costs for diabetes, heart disease, and other obesity-related conditions, those savings take years to materialize. The upfront cost hits now.
Regulatory risk persists too. The DOJ investigations into risk adjustment practices could result in significant settlements or penalties. Congressional hearings on prior authorization abuses show no signs of abating. And the public sentiment unleashed by the Thompson assassination — a raw, visceral anger at an industry perceived as prioritizing profits over patients — isn’t something a rate notice can fix.
Still, for one day at least, the market chose to focus on the numbers. And the numbers were good. A 5.06% increase, billions in additional federal funding, and a clear signal from Washington that Medicare Advantage remains too big and too popular to cut. The stocks rallied accordingly.
Whether that rally holds will depend on what happens next — in hospital negotiating rooms, in pharmacy spending reports, in federal courtrooms, and in the court of public opinion. The money is flowing. The question, as always, is whether it’s enough.
WebProNews is an iEntry Publication